Increased Vascular-Endothelial Growth Factor (VEGF) Tumor Expression and Response to Epidermal Growth Factor Receptor (EGF-R) Inhibitor Erlotinib in Non-small.

Slides:

Advertisements

Similar presentations

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

Advertisements

Molecular Therapy - Nucleic Acids

Nicotinamide Phosphoribosyltransferase: A Potent Therapeutic Target in Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor-Gene Mutation

Frances A Shepherd, MD, Rafael Rosell, MD Journal of Thoracic Oncology

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

WT1 Promotes Invasion of NSCLC via Suppression of CDH1

Abscopal Effect of Nivolumab in a Patient with Primary Lung Cancer

Dual Inhibition of the Epidermal Growth Factor Receptor with Cetuximab, an IgG1 Monoclonal Antibody, and Gefitinib, A Tyrosine Kinase Inhibitor, in Patients.

Leptomeningeal and Medullary Response to Second-Line Erlotinib in Lung Adenocarcinoma Mathilde Wagner, MD, Benjamin Besse, MD, Corinne Balleyguier, MD,

EGFR and HER2 Genomic Gain in Recurrent Non-small Cell Lung Cancer After Surgery: Impact on Outcome to Treatment with Gefitinib and Association with EGFR.

The CTC-Chip: An Exciting New Tool to Detect Circulating Tumor Cells in Lung Cancer Patients Lecia V. Sequist, MD, MPH, Sunitha Nagrath, PhD, Mehmet.

Molecular Analysis-Based Treatment Strategies for the Management of Non-small Cell Lung Cancer Howard West, MD, Rogerio Lilenbaum, MD, David Harpole,

Identification and Validation of Long Noncoding RNA Biomarkers in Human Non–Small- Cell Lung Carcinomas Hui Yu, MD, Qinghua Xu, PhD, Fang Liu, PhD, Xun.

Characterization of Fibroblast Growth Factor Receptor 1 in Small-Cell Lung Cancer Anish Thomas, MD, Jih-Hsiang Lee, MD, Zied Abdullaev, PhD, Kang-Seo.

Erlotinib Response in an NSCLC Patient with a Novel Compound G719D+L861R Mutation in EGFR Eamon M. Berge, MD, Dara L. Aisner, MD, PhD, Robert C. Doebele,

The Long Noncoding MALAT-1 RNA Indicates a Poor Prognosis in Non-small Cell Lung Cancer and Induces Migration and Tumor Growth Lars Henning Schmidt,

Dramatic Response to Low-Dose Erlotinib of Epidermal Growth Factor Receptor Mutation-Positive Recurrent Non-small Cell Lung Cancer After Severe Cutaneous.

Prognostic Impact of CD204-Positive Macrophages in Lung Squamous Cell Carcinoma: Possible Contribution of Cd204-Positive Macrophages to the Tumor-Promoting.

Combining the Multitargeted Tyrosine Kinase Inhibitor Vandetanib with the Antiestrogen Fulvestrant Enhances Its Antitumor Effect in Non-small Cell Lung.

Chandra Goparaju, PhD, Jessica S

Miliary Never-Smoking Adenocarcinoma of the Lung: Strong Association with Epidermal Growth Factor Receptor Exon 19 Deletion Eckart Laack, MD, Ronald.

Thyroid Transcription Factor-1 Amplification and Expressions in Lung Adenocarcinoma Tissues and Pleural Effusions Predict Patient Survival and Prognosis

Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement– Positive Non–Small-Cell Lung Cancer Hiroyasu Kaneda, MD, PhD, Isamu.

Prognostic Value of Vascular Endothelial Growth Factor Expression in Patients with Lung Cancer: A Systematic Review with Meta-Analysis Ping Zhan, MD,

PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non-Small-Cell Lung Cancer Denis Soulières, MD, Fred R.

Ziad Thotathil, MD, FRCR, Jeremy Long, FRACP

A Case of Squamous Cell Carcinoma Harboring an EML4-ALK Rearrangement that Was Unsuccessfully Treated with the ALK Inhibitor Alectinib Akihiro Tamiya,

Erlotinib Accumulation in Brain Metastases from Non-small Cell Lung Cancer: Visualization by Positron Emission Tomography in a Patient Harboring a Mutation.

Kelsie L. Thu, BSc, Raj Chari, PhD, William W

Serum Vascular Endothelial Growth Factor and COX-2/5-LOX Inhibition in Advanced Non-small Cell Lung Cancer: Cancer and Leukemia Group B Martin.

Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.

Christina I. Selinger, PhD, Wendy A

Upregulation of Hypoxia-Inducible Factor-1α mRNA and its Clinical Significance in Non- small Cell Lung Cancer Tomofumi Yohena, MD, Ichiro Yoshino, MD,

Role of Chromosome 3q Amplification in Lung Cancer

High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer Heounjeong Go, MD, Yoon Kyung Jeon, MD, PhD, Hyo Jin.

Clinical Significance of Epidermal Growth Factor Receptors in Non-small Cell Lung Cancer and a Prognostic Role for HER2 Gene Copy Number in Female Patients

Do Complex Mutations of the Epidermal Growth Factor Receptor Gene Reflect Intratumoral Heterogeneity? Akito Hata, MD, Shiro Fujita, MD, PhD, Reiko Kaji,

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

Erratum Journal of Thoracic Oncology

Angiogenic Markers Show High Prognostic Impact on Survival in Marginally Operable Non-small Cell Lung Cancer Patients Treated with Adjuvant Radiotherapy

A Different Method in Diagnosis of Multiple Primary Lung Cancer

Four-Year Complete Remission in a Patient with Metastatic Epidermal Growth Factor Receptor–Mutated Lung Cancer Treated with Two Cycles of Erlotinib Brendan.

A Case of ALK-Rearranged Adenocarcinoma with Small Cell Carcinoma-Like Transformation and Resistance to Crizotinib Yoon Jin Cha, MD, PhD, Byoung Chul.

Rapid Response to Trastuzumab Emtansine in a Patient with HER2-Driven Lung Cancer Daniela Weiler, MD, Joachim Diebold, MD, Klaus Strobel, MD, Stefan.

Carlos Gomez-Roca, MD, Christophe M

Osteoblastic Bone Lesions Developing During Treatment with Erlotinib Indicate Major Response in Patients with Non-small Cell Lung Cancer: A Brief Report

Novel Epidermal Growth Factor Receptor Mutation-Specific Antibodies for Non-small Cell Lung Cancer: Immunohistochemistry as a Possible Screening Method.

Nicotinamide Phosphoribosyltransferase: A Potent Therapeutic Target in Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor-Gene Mutation

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

First Case of A859T Epidermal Growth Factor Receptor Mutation Responding to Erlotinib Laureline Le Maignan, BM, Delphine Mirebeau-Prunier, MD, PhD, Laurent.

Osimertinib for Epidermal Growth Factor Receptor Mutation–Positive Lung Adenocarcinoma That Transformed to T790M-Positive Squamous Cell Carcinoma Naoyuki.

Mirror Mirror on the Wall, Who Is the Fairest of Them All

EGFR delE709_T710insD: A Rare but Potentially EGFR Inhibitor Responsive Mutation in Non–Small-Cell Lung Cancer Allison Ackerman, MD, Michael A. Goldstein,

Multiple Primary Cancers or Multiple Metastases, That Is the Question

Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies Mary Linton B Peters, MD,

T4 or MI? Journal of Thoracic Oncology Volume 6, Issue 3, (March 2011)

Rapid Detection of Hotspot Mutations in Epidermal Growth Factor Receptor by Polymerase Chain Reaction Facilitates the Management of Non-small Cell Lung.

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

Antiangiogenesis Induced Tumor Cavitation in Lung Cancer

Concomitant Epidermal Growth Factor Receptor Mutation and EML4-ALK Fusion in a Patient with Multifocal Lung Adenocarcinomas Jun Fan, MD Journal of Thoracic.

Highly Sensitive Detection of EGFR T790M Mutation in Pre-TKI Specimens of EGFR- Mutated NSCLC: In Cis, In Trans, or a Different Clone? Alvaro Leone, BSc.D

Ethnic Differences in the Management of Lung Cancer in New Zealand

Good Response to Gefitinib in Lung Adenocarcinoma Harboring Coexisting EML4-ALK Fusion Gene and EGFR Mutation Yao-Wen Kuo, MD, Shang-Gin Wu, MD, Chao-Chi.

Annemarie Becker, MD, PhD, Atie van Wijk, RN, Egbert F

A Dramatic Response to Crizotinib in a Non–Small-Cell Lung Cancer Patient with IHC- Positive and FISH-Negative ALK Jong-Mu Sun, MD, PhD, Yoon-La Choi,

Waxing and Waning of MET Amplification in EGFR-Mutated NSCLC in Response to the Presence and Absence of Erlotinib Selection Pressure Joel P. Womack,

A Review of First-Line Treatment for Small-cell Lung Cancer

MiR-1254 and miR-574-5p: Serum-Based microRNA Biomarkers for Early-Stage Non- small Cell Lung Cancer Kristen M. Foss, BS, Chao Sima, PhD, Donatella Ugolini,

Ana Luque, MD, Edurne Arriola, MD, PhD Journal of Thoracic Oncology

Presentation transcript:

Increased Vascular-Endothelial Growth Factor (VEGF) Tumor Expression and Response to Epidermal Growth Factor Receptor (EGF-R) Inhibitor Erlotinib in Non-small Cell Lung Cancer (NSCLC) Wolfgang M. Brueckl, MD, Anja Schoeberl, MD, Ralph M. Wirtz, PhD, Samuel Murray, PhD, Eckhart G. Hahn, MD, MME, FACP, Gunther H. Wiest, MD Journal of Thoracic Oncology Volume 3, Issue 3, Pages 314-316 (March 2008) DOI: 10.1097/JTO.0b013e3181654423 Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Radiological images before and after erlotinib treatment Axial, contrast-enhanced, CT images of the lungs show (A) the primary tumor (arrays) in the left lower lobe (December 2005), (B) which shrunk after treatment (April 2006). Additionally, coronal contrastenhanced CT images of the abdomen, (C) presenting with multiple liver metastases (December 2005), (D) which significantly decreased in size and number after therapy (April 2006). Journal of Thoracic Oncology 2008 3, 314-316DOI: (10.1097/JTO.0b013e3181654423) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Expression analysis of EGF-R and VEGF in the tumor and liver metastasis (A) Chromogenic in situ hybridisation (CISH) analysis showing low polysomy (array) of the EGF-R locus in the nuclei of the tumor cells. (B) Results from the expression analysis of the EGF-R and VEGF genes by quantitative real-time polymerase chain-reaction (qRT-PCR) after laser microdissection in normal lung epithelium (N), primary tumor (P) and liver metastasis (M) presenting a high VEGF overexpression in both the tumor and the metastasis. The VEGF oxerexpression could be confirmed with immunohistochemistry, (C) showing a strong cytoplasmatic staining (dark red) of both the primary lung tumor cells and (D) the liver metastasis using anti-VEGF antibodies. Journal of Thoracic Oncology 2008 3, 314-316DOI: (10.1097/JTO.0b013e3181654423) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions